Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a large decline in short interest in February. As of February 15th, there was short interest totalling 149,800 shares, a decline of 35.5% from the January 31st total of 232,100 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average trading volume of 77,600 shares, the short-interest ratio is currently 1.9 days.

Analysts Set New Price Targets

Separately, Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th.

Marker Therapeutics Price Performance

MRKR stock traded down $0.07 during midday trading on Tuesday, hitting $1.38. 56,554 shares of the company’s stock were exchanged, compared to its average volume of 71,326. Marker Therapeutics has a 12-month low of $1.35 and a 12-month high of $5.99. The firm has a 50 day moving average price of $2.22 and a 200-day moving average price of $2.99.

Insider Buying and Selling

In related news, Director Steve Elms purchased 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, with a total value of $35,472.00. Following the transaction, the director now owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. The trade was a 3.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Enterprise Associates 16 New purchased 554,250 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the transaction, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. This represents a 51.73 % increase in their position. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Marker Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MRKR. Invst LLC purchased a new stake in Marker Therapeutics during the 3rd quarter worth approximately $56,000. LPL Financial LLC bought a new stake in shares of Marker Therapeutics in the 4th quarter valued at approximately $248,000. Aisling Capital Management LP increased its holdings in shares of Marker Therapeutics by 3.5% in the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after acquiring an additional 11,084 shares during the last quarter. Blue Owl Capital Holdings LP bought a new stake in shares of Marker Therapeutics in the 4th quarter valued at approximately $1,724,000. Finally, Northern Trust Corp increased its holdings in shares of Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after acquiring an additional 21,703 shares during the last quarter. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.